COVID-19NCT04401254
Recovery of Patients From COVID-19 After Critical Illness
An observational study of COVID-19 and Critical Illness, run by Australian and New Zealand Intensive Care Research Centre at 29 sites in Australia.
Trial summary
Patients who are critically ill with COVID-19 requiring life support in an intensive care unit (ICU) have increased risk of morbidity and mortality. Currently the ICU community does not know what effect the disease, the ICU admission, physiotherapy interventions and life support have on their long-term quality of life… Read more about this study
- Who is it for?
- Ages 17 years and older
- Conditions the study is for
- COVID-19, Critical Illness
- How many people
- 536 participants
- Where
- 29 sitesAustralia
- Study dates
- 1 Jul 2020to 30 Jul 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 17 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Critically ill patients with COVID-19 admitted to an intensive care unit
Who may be able to join
- COVID-19 patients who have been admitted to ICU for > 24 hours
- Patients aged over 17 years
- Persistent critical illness cohort
- As above
- An ICU admission of at least 10 consecutive days
Who cannot join
- Previous enrolment in this study in a prior ICU admission
Trial locations and contacts
29 sites in 1 country.
29 sites in 1 country
Australia29 sites
Royal Adelaide Hospital
Adelaide, South Australia, 5000
Casey Hospital
Berwick, Victoria, 3806
Box Hill Hospital (Eastern Health)
Box Hill, Victoria, 3128
Royal Prince Alfred Hospital
Camperdown, New South Wales, 2050
The Prince Charles Hospital
Chermside, Queensland, 4032
Monash Medical Centre
Clayton, Victoria, 3168
Concord Hospital
Concord, New South Wales, 2139
Dandenong Hospital
Dandenong, Victoria, 3175
St Vincent's Hospital Sydney
Darlinghurst, New South Wales, 2010
St Vincent's Hospital Melbourne
Fitzroy, Victoria, 3065
Footscray Hospital
Footscray, Victoria, 3011
Frankston Hospital
Frankston, Victoria, 3199
Canberra Hospital
Garran, Australian Capital Territory, 2605
Austin Hospital
Heidelberg, Victoria, 3084
Royal Brisbane and Women's Hospital
Herston, Queensland, 4029
Nepean Hospital
Kingswood, New South Wales, 2747
St George Hospital
Kogarah, New South Wales, 2217
Launceston Hospital
Launceston, Tasmania, 7250
Cabrini Health
Malvern, Victoria, 3144
Australian New Zealand Intensive Care Research Centre
Melbourne, Victoria, 3004
John Hunter Hospital
New Lambton Heights, New South Wales, 2305
Royal Melbourne Hospital
Parkville, Victoria, 3050
Alfred Hospital
Prahran, Victoria, 3004
Redcliffe Hospital
Redcliffe, Queensland, 4020
Royal North Shore Hospital
Saint Leonards, New South Wales, 2065
Gold Coast Hospital
Southport, Queensland, 4215
Sunshine Hospital
St Albans, Victoria, 3021
Westmead Hospital
Westmead, New South Wales, 2145
Princess Alexandra Hospital
Woolloongabba, Queensland, 4102
About this study
Official title: The Coronavirus Disease 2019 - Recovery Study
Patients who are critically ill with COVID-19 requiring life support in an intensive care unit (ICU) have increased risk of morbidity and mortality. Currently the ICU community does not know what effect the disease, the ICU admission, physiotherapy interventions and life support have on their long-term quality of life and whether they can return to their pre-illness level of function following ICU.
COVID-Recovery will describe the physiotherapy interventions delivered to critically ill patients with COVID-19. In survivors, COVID-Recovery will utilise telephone follow-up of ICU survivors to assess disability-free survival and quality of life at 6 months after ICU admission. Additionally, COVID-Recovery will identify if there are predictors of disability-free survival. COVID-Recovery will aim to select up to 300 patients diagnosed with COVID-19 from ICUs in Australia. If they survive to hospital discharge, patients will be invited to receive a telephone questionnaire at 6 months after the ICU admission that aims to assess their long-term outcomes, including physical, cognitive and emotional function, quality of life, and whether they have been able to return to work following ICU discharge.
Read more
To describe the experience of critical illness in survivors of COVID-19 and their family members.
To explore and describe functional recovery, respiratory system function and respiratory health morbidity up to 6 months after ICU admission in persistently critically ill adults with COVID-19
- Conditions
- COVID-19, Critical Illness
- Keywords
- recovery
- Medical subject headings
- COVID-19, Critical Illness
What is being measured
The primary outcome is the main question the study is designed to answer.
Disability-free survival
a composite measure of WHODAS 2.0 - 12 level and hospital survival
Measured: 6 months
Physiotherapy intervention
The physiotherapy interventions provided to patients with COVID-19 admitted to the ICU and health outcomes
Measured: During the ICU stay until 3 months
Secondary outcomes (11)
Health status
Health related quality of life measured with EQ5D-5L score from 0 to 100
Measured: 6 months
Global function
World Health Organization Disability Assessment Schedule 2.0 12L
Measured: 6 months
Cognitive function
Montreal Cognitive Assessment Blind
Measured: 6 months
Anxiety and depression
Hospital Anxiety and Depression Scale
Measured: 6 months
Screening for post-traumatic distress
Impact of Events Scale Revised
Measured: 6 months
Work Status
WHODAS 2.0
Measured: 6 months
Proportion of patients with COVID-19 who received physiotherapy in ICU
Measured: During the ICU stay until 28 days
The reported barriers to delivering physiotherapy interventions
Physiotherapist reported barriers to delivering the intervention
Measured: During the ICU stay until 28 days
Adverse events during physiotherapy interventions
Adverse events that require the intervention to be ceased for medical intervention
Measured: During the ICU stay until 28 days
Phenomenological data of the patient and family experience
Qualitative interviews
Measured: 6 months
Global function
Global Rating of Change
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 May 2020
- Study start1 Jul 2020
- Primary completion30 Jul 2022
- Study completion30 Jul 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for COVID-19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 536 participants (actual)
Sponsor and investigators
- Lead sponsor
- Australian and New Zealand Intensive Care Research Centre
- Sponsor type
- University, hospital or other
- Collaborators
- The Alfred
- Responsible party
- Sponsor
- Investigators
- Carol Hodgson, PhD, Principal investigator, Monash University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04401254
- Sponsor's protocol ID
- COVID-Recovery V1.5 9Feb2022
- Status last verified
- Sep 2022
- First submitted
- 7 May 2020
- Last updated
- 28 Sep 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: IPD will be shared if approved by the steering committee and with ethical approvals.
Publications
Hodgson CL, Higgins AM, Bailey MJ, Mather AM, Beach L, Bellomo R, Bissett B, Boden IJ, Bradley S, Burrell A, Cooper DJ, Fulcher BJ, Haines KJ, Hodgson IT, Hopkins J, Jones AYM, Lane S, Lawrence D, van der Lee L, Liacos J, Linke NJ, Gomes LM, Nickels M, Ntoumenopoulos G, Myles PS, Patman S, Paton M, Pound G, Rai S, Rix A, Rollinson TC, Tipping CJ, Thomas P, Trapani T, Udy AA, Whitehead C, Anderson S, Neto AS; COVID-Recovery Study Investigators and the ANZICS Clinical Trials Group. Comparison of 6-Month Outcomes of Survivors of COVID-19 versus Non-COVID-19 Critical Illness. Am J Respir Crit Care Med. 2022 May 15;205(10):1159-1168. doi: 10.1164/rccm.202110-2335OC.
PubMed 35258437Hodgson CL, Higgins AM, Bailey MJ, Mather AM, Beach L, Bellomo R, Bissett B, Boden IJ, Bradley S, Burrell A, Cooper DJ, Fulcher BJ, Haines KJ, Hopkins J, Jones AYM, Lane S, Lawrence D, van der Lee L, Liacos J, Linke NJ, Gomes LM, Nickels M, Ntoumenopoulos G, Myles PS, Patman S, Paton M, Pound G, Rai S, Rix A, Rollinson TC, Sivasuthan J, Tipping CJ, Thomas P, Trapani T, Udy AA, Whitehead C, Hodgson IT, Anderson S, Neto AS; COVID-Recovery Study Investigators and the ANZICS Clinical Trials Group. The impact of COVID-19 critical illness on new disability, functional outcomes and return to work at 6 months: a prospective cohort study. Crit Care. 2021 Nov 8;25(1):382. doi: 10.1186/s13054-021-03794-0.
PubMed 34749756
Study at a glance
From the registry record, last updated by the sponsor on 28 Sep 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Coronavirus Disease 2019 - Recovery Study
- ClinicalTrials.gov ID
- NCT04401254
- Acronym / sponsor ID
- COVID-Recovery V1.5 9Feb2022
- Conditions
- COVID-19, Critical Illness
- Keywords
- recovery
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 536 participants (actual)
- Lead sponsor
- Australian and New Zealand Intensive Care Research CentreUniversity, hospital or other
- Collaborators
- The Alfred
- Study start
- 1 Jul 2020 (actual)
- Primary completion
- 30 Jul 2022 (actual)
- Study completion
- 30 Jul 2022 (actual)
- First posted
- 26 May 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients who are critically ill with COVID-19 requiring life support in an intensive care unit (ICU) have increased risk of morbidity and mortality. Currently the ICU community does not know what effect the disease, the ICU admission, physiotherapy interventions and life support have on their long-term quality of life and whether they can return to their pre-illness level of function following ICU.
COVID-Recovery will describe the physiotherapy interventions delivered to critically ill patients with COVID-19. In survivors, COVID-Recovery will utilise telephone follow-up of ICU survivors to assess disability-free survival and quality of life at 6 months after ICU admission. Additionally, COVID-Recovery will identify if there are predictors of disability-free survival. COVID-Recovery will aim to select up to 300 patients diagnosed with COVID-19 from ICUs in Australia. If they survive to hospital discharge, patients will be invited to receive a telephone questionnaire at 6 months after the ICU admission that aims to assess their long-term outcomes, including physical, cognitive and emotional function, quality of life, and whether they have been able to return to work following ICU discharge.
To describe the experience of critical illness in survivors of COVID-19 and their family members.
To explore and describe functional recovery, respiratory system function and respiratory health morbidity up to 6 months after ICU admission in persistently critically ill adults with COVID-19
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 17 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Critically ill patients with COVID-19 admitted to an intensive care unit
Key inclusion criteria (5 listed)
- COVID-19 patients who have been admitted to ICU for > 24 hours
- Patients aged over 17 years
- Persistent critical illness cohort
- As above
- An ICU admission of at least 10 consecutive days
Key exclusion criteria (1 listed)
- Previous enrolment in this study in a prior ICU admission
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Disability-free survival
Time frame: 6 months
a composite measure of WHODAS 2.0 - 12 level and hospital survival
Physiotherapy intervention
Time frame: During the ICU stay until 3 months
The physiotherapy interventions provided to patients with COVID-19 admitted to the ICU and health outcomes
11 secondary outcomes
Health status
Time frame: 6 months
Global function
Time frame: 6 months
Cognitive function
Time frame: 6 months
Anxiety and depression
Time frame: 6 months
Screening for post-traumatic distress
Time frame: 6 months
Work Status
Time frame: 6 months
Proportion of patients with COVID-19 who received physiotherapy in ICU
Time frame: During the ICU stay until 28 days
The reported barriers to delivering physiotherapy interventions
Time frame: During the ICU stay until 28 days
Adverse events during physiotherapy interventions
Time frame: During the ICU stay until 28 days
Phenomenological data of the patient and family experience
Time frame: 6 months
Global function
Time frame: 6 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Sep 2022.
- Derived from this study: PubMed 35258437Hodgson CL, Higgins AM, Bailey MJ, Mather AM, Beach L, Bellomo R, Bissett B, Boden IJ, Bradley S, Burrell A, Cooper DJ, Fulcher BJ, Haines KJ, Hodgson IT, Hopkins J, Jones AYM, Lane S, Lawrence D, van der Lee L, Liacos J, Linke NJ, Gomes LM, Nickels M, Ntoumenopoulos G, Myles PS, Patman S, Paton M, Pound G, Rai S, Rix A, Rollinson TC, Tipping CJ, Thomas P, Trapani T, Udy AA, Whitehead C, Anderson S, Neto AS; COVID-Recovery Study Investigators and the ANZICS Clinical Trials Group. Comparison of 6-Month Outcomes of Survivors of COVID-19 versus Non-COVID-19 Critical Illness. Am J Respir Crit Care Med. 2022 May 15;205(10):1159-1168. doi: 10.1164/rccm.202110-2335OC.
- Derived from this study: PubMed 34749756Hodgson CL, Higgins AM, Bailey MJ, Mather AM, Beach L, Bellomo R, Bissett B, Boden IJ, Bradley S, Burrell A, Cooper DJ, Fulcher BJ, Haines KJ, Hopkins J, Jones AYM, Lane S, Lawrence D, van der Lee L, Liacos J, Linke NJ, Gomes LM, Nickels M, Ntoumenopoulos G, Myles PS, Patman S, Paton M, Pound G, Rai S, Rix A, Rollinson TC, Sivasuthan J, Tipping CJ, Thomas P, Trapani T, Udy AA, Whitehead C, Hodgson IT, Anderson S, Neto AS; COVID-Recovery Study Investigators and the ANZICS Clinical Trials Group. The impact of COVID-19 critical illness on new disability, functional outcomes and return to work at 6 months: a prospective cohort study. Crit Care. 2021 Nov 8;25(1):382. doi: 10.1186/s13054-021-03794-0.
- Individual participant dataSharing planned: Yes. IPD will be shared if approved by the steering committee and with ethical approvals.
Related trials for COVID-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Carol Hodgson, PhD principal investigator
Monash University
29 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of COVID-19 and Critical Illness, run by Australian and New Zealand Intensive Care Research Centre at 29 sites in Australia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Sep 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 29 sites in Australia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Disability-free survival (time frame: 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04401254, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Sep 2022.